Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Ongoren, Seniz; Eskazan, Ahmet; Suzan, Veysel; Savci, Sercan; Ozunal, Isil; Berk, Selin; Yalniz, Fevzi; Elverdi, Tuğrul; Salihoglu, Ayse; Erbilgin, Yücel; Iseri, Sibel; Ar, Muhlis; Baslar, Zafer; Aydin, Yildiz; Tuzuner, Nukhet; Ozbek, Ugur; Soysal, Teoman

doi:10.1080/10245332.2017.1385193

Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Ongoren S., Eskazan A. E., Suzan V., Savci S., Ozunal I. E., Berk S., ...Daha Fazla

Hematology (Amsterdam, Netherlands), cilt.23, sa.4, ss.212-220, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 23 Sayı: 4
Basım Tarihi: 2018
Doi Numarası: 10.1080/10245332.2017.1385193
Dergi Adı: Hematology (Amsterdam, Netherlands)
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.212-220
İstanbul Üniversitesi Adresli: Evet

Özet

Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.